Meet Medtel’s Chief Growth & Strategy Officer
Sarajian spent the first 11 years of his career at Thomson Healthcare (Thomson Reuters) and held a number of sales & marketing and corporate positions including the appointment as General Manager of Thomson’s first Chinese JV with the Ministry of Public Health.
He left Thomson to Co-Found Equilar, which developed technology to mine and store content from SEC filings. Equilar’s algorithms centralize data from numerous filings and calculated Black Scholes valuations to arrive at total direct compensation. Equilar quickly became and remains the standard for Executive Compensation and BOD analysis.
After his successful exit from Equilar, Michael returned to healthcare and launched and operated r4 Vascular, a VC backed vascular access company that used advanced flow dynamics and radiopaque materials to develop low profile high pressure balloons and implantable ports. R4 grew to over sixty FTEs and combined assets with other portfolio companies during the financial crisis.
Sarajian then founded Health Recovery Partners a cloud-based hospital revenue cycle company designed to use data driven resolution pathways to personalize self-pay patient responsibility and invested in Agora Dental which uses real time financial metrics to align dental procedure pricing with scheduling utilization trends.
Most recently, in 2016 Michael became Chief Revenue Officer of Spaulding Medical which was developing mobile cardiac hardware, software & analytics for hospitals, clinics and patients. In 2019, his responsibilities expanded and he assume the CRO role at Spaulding Clinical, a sister company focused on Phase 1 Clinical Trials. Under his leadership, Spaulding’s collective revenues increased from $11.5M to over $36M.
He has an MBA from Fordham University.